Table 1 Pretreatment patient characteristics
Patient characteristics | |
|---|---|
Number of patients | 37 |
Median age (range) | 71.4 years (57.6–83.9) |
Disease extent | |
Localised | 1 |
Bone mets only | 13 |
Bone+nodal disease | 16 |
Bone+liver/lung | 7 |
Performance score | |
0 | 2 |
1 | 18 |
2 | 11 |
3 | 5 |
Missing | 1 |
Symptomatic | |
No | 3 |
Yes | 33 |
Missing | 1 |
Primary therapy | |
GnRH | 18 |
MAB | 13 |
Orchidectomy | 3 |
Antiandrogen monotherapy | 3 |
PSA levels at start CL56 | |
Median and (range) | 183.5 (11.3–1560) |
Alkaline phosphatase at start of CL56 | |
⩽120 | 18 |
>120 | 19 |
Gleason score | |
8–10 | 6 |
5–7 | 17 |
⩽4 | 3 |
Missing | 11 |
PSA normalised with prior androgen deprivation | |
No | 16 |
Yes | 15 |
Missing | 6 |
Median time to androgen independence (AI) | 25 months (range 4.4–136.7) |
Number AI<2 years | 17 |
Number AI>2 years | 20 |
Median time AI to start study | 14.3 months (range 1.8–46.2) |
Number AI to start study<1 year | 17 |
Number AI to start study >1 year | 20 |
